For vaccine - GLOBE NETWORK

More documents

Recommendations

Info

Phased introduction • Advantages – Real data for country and region – Accurate cost‐effectiveness analysis – What alternatives are there? • Blind introduction?
What of serotype replacement? • Options – Ignore and hope for the best – Monitor carriage patterns – Monitor IPD in sentinel sites – Monitor IPD in high risk groups – Try to monitor impact on pneumonia rates
Page 1 and 2: How to determine the effectiveness
Page 3 and 4: But difficult questions have arisen
Page 5 and 6: Bohol study of PCV‐11 • 12,194
Page 7 and 8: But difficult questions have arisen
Page 9 and 10: So the key questions are… • How
Page 11 and 12: Before and after… • Need consis
Page 13 and 14: ARI surveillance system Viet Nam Ta
Page 15 and 16: Seasonal Prevalence of Major Pediat
Page 17 and 18: Before and after ‐ conclusions
Page 19 and 20: Community controls • Usually matc
Page 21 and 22: Potential for bias • Community co
Page 23 and 24: Lau et al. Acta Paediatr 1995;84:17
Page 25 and 26: An Effectiveness Trial of Hib Vacci
Page 27 and 28: How to establish the effectiveness
Page 29 and 30: Lancet 2005;365:43‐52
Page 31 and 32: Pneumonia results Incidences per 10
Page 33 and 34: Consider country X • East Asia
Page 35: Phased introduction • Risks - May
Page 39 and 40: IPD in high risk groups • Immunoc

For vaccine - GLOBE NETWORK

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?